SLC5A2 and heart failure: This study investigated which cases are more suitable for Vericiguat, acting as “a brace (in Japanese, sujikai) supporting all or any of the Four Pillars” among patients with heart failure receiving therapy based on the four standard cardioprotective drugs, which include not only MRAs, beta-blockers, and Sacubitril/Valsartan but also SGLT2 inhibitors, in actual clinical practice in Japan.